Predictive Oncology Inc. (Nasdaq: POAI), relating to the proposed merger with Renovaro Inc. Under the terms of the agreement, Renovaro will acquire 100% of Predictive Oncology common shares through the issuance of Preferred stock, which shall be redeemed by Renovaro for $3.00 per share not later than 18 months after closing of the merger.